Diagnostic biomarker of asbestos-related mesothelioma: Example of translational research

Cancer Science

Volumn 98, Issue 8, 2007, Pages 1147-1151

  Okio, Hino ^a   Kazu, Shiomi ^a   Masahiro, Maeda ^b  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Immuno Biological Laboratories Co Ltd   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; BIOLOGICAL MARKER; CISPLATIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESOTHELIN; MITOGEN ACTIVATED PROTEIN KINASE 1; PEMETREXED; TRANSCRIPTION FACTOR AP 1; TUMOR MARKER; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1;

CANCER RESEARCH; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; ENVIRONMENTAL FACTOR; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INCUBATION TIME; LUNG CARCINOGENESIS; NONHUMAN; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; REVIEW;

ANIMALS; ASBESTOS; ENVIRONMENTAL EXPOSURE; ENZYME-LINKED IMMUNOSORBENT ASSAY; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; MESOTHELIOMA; ONCOGENE PROTEINS; PERITONEAL NEOPLASMS; PLEURAL NEOPLASMS; RATS; TUMOR MARKERS, BIOLOGICAL;

EID: 34347233115     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00520.x     Document Type: Review

References (26)

1. Knudson AG. Hereditary cancer, oncogenes and antioncogenes. Cancer Res 1985; 45: 1437-43.
2. Knudson AG Jr. Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971; 68: 820-3.
3. Hino O, Majima S, Kobayashi T et al. Multistep renal carcinogenesis as gene expression disease in tumor suppressor TSC2 gene mutant model -genotype, phenotype and environment. Mutat Res 2001; 477: 155-64.
4. Eker R, Mossige JA. A dominant gene for renal adenomas in the rat. Nature 1961; 189: 858-9.
5. Kouchi M, Okimoto K, Matsumoto I, Tanaka K, Yasuba M, Hino O. Natural history of the Nihon (Bhd gene mutant) rat, a novel model for human Birt-Hogg-Dube syndrome. Virchows Arch 2006; 448: 463-71.
6. Hino O, Kobayashi E, Nishizawa M et al. Renal carcinogenesis in the Eker rat. J Cancer Res Clin Oncol 1995; 121: 602-5.
7. Yamashita Y, Yokoyama M, Kobayashi E, Takai S, Hino O. Mapping and determination of the cDNA sequence of the Erc gene preferentially expressed in renal cell carcinoma in the Tsc2 gene mutant (Eker) rat model. Biochem Biophys Res Commun 2000; 275: 134-40.
8. Carbone M, Emri S, Dogan AU et al. A mesothelioma epidemic in Cappadocia: Scientific developments and unexpected social outcomes. Nat Rev Cancer 2007; 7: 147-54.
9. Morinaga K, Kishimoto T, Sakatani M, Akira M, Yokoyama K, Sera Y. Asbestos-related lung cancer and mesothelioma in Japan. Ind Health 2001; 39: 65-74.
10. Rowinsky EK, Beeram M, Hammond LA et al. A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies. Clin Cancer Res 2007; 13: 532-9.
11. Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed: Biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 2007; 6: 404-17.
12. Green J, Dundar Y, Dodd S, Dickson R, Walley T. Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma. Cochrane Database of Systematic Reviews 2007 (Jan 24); Issue 1: CD005574.
13. Maeda M, Hino O. Molecular tumor markers for asbestos-related mesothelioma: Serum diagnostic markers. Pathol Int 2006; 56: 649-54.
14. Maeda M, Hino O. Blood test for asbestos-related mesothelioma. Oncology 2006; 71: 26-31. [Epub 2007 Mar 5.]
15. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 1996; 93: 136-40.
16. Shiomi K, Miyamoto H, Segawa T et al. A novel ELISA system for detection of a 'N-ERC/Mesothelin'in the sera of mesothelioma patients. Cancer Sci 2006; 97: 928-32.
17. Onda M, Nagata S, Ho M et al. Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin Cancer Res 2006; 12: 4225-31.
18. Robinson BW, Creaney J, Lake R et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003; 362: 1612-16.
19. Robinson BW, Creaney J, Lake R et al. Soluble mesothelin related protein: A blood test for mesothelioma. Lung Cancer 2005; 49: S109-11.
20. Scherpereel A, Grigoriu B, Conti M et al. Soluble mesothelin related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006; 173: 1155-60.
21. Beyer HL, Geschwindt RD, Glover CL et al. MESOMARKTM: A potential test for malignant pleural mesothelioma. Clin Chem 2007; 53: 666-72. [Epub 2007 Feb 8.]
22. Hassan R, Bera T, Pastan I. Mesothelin: A new target for immunotherapy. Clin Cancer Res 2004; 10: 3937-42.
23. Onda M, Willingham M, Nagata S et al. New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA. Clin Cancer Res 2005; 11: 5840-6.
24. Hassan R, Remaley AT, Sampson ML et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 2006; 12: 447-53.
25. Dogan AU, Baris YI, Emri S, Steele I, Elmishad AG, Carbone M. Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey. Cancer Res 2006; 66: 5063-8.
26. Nakaishi M, Kajino K, Ikesue M et al. Establishment of the enzyme-linked immunosorbent assay system to detect the amino terminal secretory form of rat Erc/Mesothelin. Cancer Sci 2007; 98: 659-64.